Actuate Therapeutics (ACTU) Competitors $8.61 -0.06 (-0.69%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ACTU vs. LENZ, PRAX, ZYME, CMRX, CDMO, NUVB, QURE, XERS, IMNM, and PHARShould you be buying Actuate Therapeutics stock or one of its competitors? The main competitors of Actuate Therapeutics include LENZ Therapeutics (LENZ), Praxis Precision Medicines (PRAX), Zymeworks (ZYME), Chimerix (CMRX), Avid Bioservices (CDMO), Nuvation Bio (NUVB), uniQure (QURE), Xeris Biopharma (XERS), Immunome (IMNM), and Pharming Group (PHAR). These companies are all part of the "pharmaceutical products" industry. Actuate Therapeutics vs. Its Competitors LENZ Therapeutics Praxis Precision Medicines Zymeworks Chimerix Avid Bioservices Nuvation Bio uniQure Xeris Biopharma Immunome Pharming Group LENZ Therapeutics (NASDAQ:LENZ) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership. Do analysts recommend LENZ or ACTU? LENZ Therapeutics presently has a consensus price target of $46.60, suggesting a potential upside of 57.54%. Actuate Therapeutics has a consensus price target of $20.50, suggesting a potential upside of 138.10%. Given Actuate Therapeutics' higher possible upside, analysts clearly believe Actuate Therapeutics is more favorable than LENZ Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LENZ Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Actuate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor LENZ or ACTU? LENZ Therapeutics received 12 more outperform votes than Actuate Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformLENZ TherapeuticsOutperform Votes15100.00% Underperform VotesNo VotesActuate TherapeuticsOutperform Votes3100.00% Underperform VotesNo Votes Does the media refer more to LENZ or ACTU? In the previous week, LENZ Therapeutics had 4 more articles in the media than Actuate Therapeutics. MarketBeat recorded 5 mentions for LENZ Therapeutics and 1 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 1.87 beat LENZ Therapeutics' score of 1.10 indicating that Actuate Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment LENZ Therapeutics Positive Actuate Therapeutics Very Positive Do institutionals & insiders have more ownership in LENZ or ACTU? 54.3% of LENZ Therapeutics shares are held by institutional investors. 6.9% of LENZ Therapeutics shares are held by insiders. Comparatively, 69.3% of Actuate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is LENZ or ACTU more profitable? Actuate Therapeutics' return on equity of 0.00% beat LENZ Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets LENZ TherapeuticsN/A -58.48% -55.50% Actuate Therapeutics N/A N/A N/A Which has preferable earnings and valuation, LENZ or ACTU? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLENZ TherapeuticsN/AN/A-$124.65M-$1.77-16.71Actuate TherapeuticsN/AN/A-$24.75MN/AN/A SummaryLENZ Therapeutics and Actuate Therapeutics tied by winning 6 of the 12 factors compared between the two stocks. Get Actuate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACTU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACTU vs. The Competition Export to ExcelMetricActuate TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$168.93M$6.94B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E RatioN/A8.7927.2619.97Price / SalesN/A263.06412.06157.64Price / CashN/A65.8538.2534.64Price / BookN/A6.597.064.69Net Income-$24.75M$144.20M$3.24B$248.14M7 Day Performance-5.28%3.81%2.56%2.39%1 Month Performance-17.61%11.10%8.75%6.06%1 Year PerformanceN/A3.95%31.30%13.57% Actuate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACTUActuate TherapeuticsN/A$8.61-0.7%$20.50+138.1%N/A$168.93MN/A0.0010LENZLENZ Therapeutics1.6791 of 5 stars$29.16-0.1%$46.60+59.8%+58.1%$820.74MN/A-16.47110Positive NewsPRAXPraxis Precision Medicines2.5563 of 5 stars$39.82+3.3%$109.90+176.0%+13.2%$811.09M$8.12M-3.87110Analyst ForecastZYMEZymeworks1.902 of 5 stars$11.64+1.8%$21.00+80.4%+34.0%$809.88M$93.38M-7.76460Positive NewsCMRXChimerix0.6755 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212K-9.0990CDMOAvid Bioservices0.8395 of 5 stars$12.50+0.1%$12.25-2.0%+56.4%$799.18M$139.91M-5.23320High Trading VolumeNUVBNuvation Bio2.9872 of 5 stars$2.34+10.1%$7.83+235.5%-22.5%$794.51M$10.96M-1.0860Trending NewsAnalyst ForecastHigh Trading VolumeQUREuniQure2.0618 of 5 stars$14.48+0.1%$37.82+161.2%+210.1%$793.16M$20.20M-2.92500News CoverageAnalyst RevisionXERSXeris Biopharma3.9191 of 5 stars$5.05+2.2%$6.25+23.8%+90.4%$789.74M$222.55M-11.22290Analyst RevisionIMNMImmunome1.7887 of 5 stars$9.06+3.4%$23.33+157.5%-39.6%$788.33M$10.94M-1.1240Positive NewsPHARPharming Group2.0584 of 5 stars$11.48+8.3%$30.00+161.3%+32.9%$781.00M$320.71M-44.15280News CoverageShort Interest ↑Gap Up Related Companies and Tools Related Companies LENZ Competitors PRAX Competitors ZYME Competitors CMRX Competitors CDMO Competitors NUVB Competitors QURE Competitors XERS Competitors IMNM Competitors PHAR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACTU) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actuate Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Actuate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
